世界卫生组织中枢神经系统肿瘤分类的演变：1979-2021年

doi:10.3969/j.issn.1672-6731.2021.09.002

摘要/Abstract

摘要：

简要回顾世界卫生组织（WHO）中枢神经系统肿瘤分类历史，重点介绍1979年（第一版）至2021年（第五版）WHO中枢神经系统肿瘤分类的演变，包括肿瘤分类框架、类型/亚型和分级。本文讲述第一版至第四版以组织学为基础的分类，历经第四版修订版的尝试以及中枢神经系统肿瘤分类分子信息及实践方法联盟-非WHO官方组织的7次更新，发展到2021年WHO中枢神经系统肿瘤分类（简称新版肿瘤分类）中更多的由生物学和分子特征定义的肿瘤实体。儿童型弥漫性胶质瘤由于分子遗传学不同，从弥漫性胶质瘤中独立出来，也是新版肿瘤分类的重要变化之一。本文还以新版肿瘤分类中中枢神经系统肿瘤实体为线索，介绍各个类别肿瘤类型/亚型的演变，包括因何增加、删除或更改命名。新版肿瘤分类中中枢神经系统肿瘤分级方法力求为与非中枢神经系统肿瘤分级相一致，分级标准在组织学特征的基础上增加分子参数。新版肿瘤分类为临床诊疗设定了新标准，期待未来可以促进临床研究和基础科学研究。

关键词: 中枢神经系统肿瘤, 指南, 世界卫生组织, 医学史, 综述

Abstract:

In this article, we look back on history of the classification of tumors of central nervous system(CNS) in brief, and further review the evolution of WHO Classification of Tumors of CNS from the first edition to the fifth edition (WHO CNS5), including the category frame, tumor type/subtype and tumor grading. Changed from histology based classification into more biologically and molecularly defined entities, WHO CNS5 was recently released as expected, after attempt in WHO CNS4 updated version and 7 update publications upon the work of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy-Not Official WHO (cIMPACT-NOW). One of the important changes in WHO CNS5 is the separating gliomas into pediatric-type and adult-type based on their well-established molecular genetic differences. Tracing alone the clue in WHO CNS5, we introduce evolutionary process of entities and subtypes under each categories, and try to explain why they were added, deleted or why their naming was changed from WHO CNS1 to WHO CNS5. Tumor grading in WHO CNS5 has make efforts on moving close to how grading is done for non-CNS neoplasms, and added molecular parameters as biomarkers of grading based on histological features. WHO CNS5 has set new standers for clinical management of CNS tumors, and has been expected to facilitate related clinical studies and basic research in the future.

Key words: Central nervous system neoplasmas, Guidelines, World Health Organization, History of medicine, Review

杨学军, 江涛, 陈忠平, 于士柱. 世界卫生组织中枢神经系统肿瘤分类的演变：1979-2021年[J]. 中国现代神经疾病杂志, 2021, 21(9): 710-724.

YANG Xue-jun, JIANG Tao, CHEN Zhong-ping, YU Shi-zhu. The evolution of WHO Classification of Tumors of the Central Nervous System from 1979 to 2021[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2021, 21(9): 710-724.

https://journal11.magtechjournal.com/cjcnn/CN/Y2021/V21/I9/710

参考文献

[1] Yang XJ. From the neurosurgeons' angle to interpret the development of histological classification of central nervous system tumor[J]. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2008, 8:376-383. [杨学军. 从神经外科医师角度解读中枢神经系统肿瘤组织学分类的发展[J]. 中国现代神经疾病杂志, 2008, 8:376-383.]
[2] Yang SY, Yang XJ. Overview of intracranial tumors[M]//Yang SY, Zhi DS. Neurosurgery. Beijing:People's Medical Publishing House, 2008:455-484. [杨树源, 杨学军. 颅内肿瘤总论[M]//杨树源, 只达石. 神经外科学. 北京:人民卫生出版社, 2008:455-484.]
[3] Yang XJ. Overview of intracranial tumors[M]//Yang SY, Zhang JN. Neurosurgery. 2nd ed. Beijing:People's Medical Publishing House, 2015:445-465. [杨学军. 颅内肿瘤总论[M]//杨树源, 张建宁. 神经外科学. 2版. 北京:人民卫生出版社, 2015:445-465.]
[4] Zülch KJ. Principles of the new World Health Organization (WHO) classification of brain tumors[J]. Neuroradiology, 1980, 19:59-66.
[5] Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours[J]. Brain Pathol, 1993, 3:255-268.
[6] Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK. The WHO classification of tumors of the nervous system[J]. J Neuropathol Exp Neurol, 2002, 61:215-225.
[7] Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system[J]. Acta Neuropathol, 2007, 114:97-109.
[8] Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System:a summary[J]. Acta Neuropathol, 2016, 131:803-820.
[9] Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO Classification of Tumors of the Central Nervous System:a summary[J]. Neuro Oncol, 2021, 23:1231-1251.
[10] Yang XJ. Interpretation of WHO Classification of Central Nervous System Tumours (2007)[J]. Zhongguo Shen Jing Jing Shen Ji Bing Za Zhi, 2007, 33:513-517. [杨学军. 解读《世界卫生组织中枢神经系统肿瘤分类(2007年)》[J]. 中国神经精神疾病杂志, 2007, 33:513-517.]
[11] Yang XJ, Jiang T. Interpretation of World Health Organization Classification of Central Nervous System Tumors (2016)[J]. Zhongguo Shen Jing Jing Shen Ji Bing Za Zhi, 2016, 42:321-329. [杨学军, 江涛. 解读《世界卫生组织中枢神经系统肿瘤分类(2016年)》[J]. 中国神经精神疾病杂志, 2016, 42:321-329.]
[12] Li JB, Wang XY, Tong LQ, Yang XJ, Brat DJ. A contemporary molecular view of diffuse gliomas with implications for diagnosis[J]. Glioma, 2020, 3:38-44.
[13] Louis DN, Wesseling P, Aldape K, Brat DJ, Capper D, Cree IA, Eberhart C, Figarella-Branger D, Fouladi M, Fuller GN, Giannini C, Haberler C, Hawkins C, Komori T, Kros JM, Ng HK, Orr BA, Park SH, Paulus W, Perry A, Pietsch T, Reifenberger G, Rosenblum M, Rous B, Sahm F, Sarkar C, Solomon DA, Tabori U, van den Bent MJ, von Deimling A, Weller M, White VA, Ellison DW. cIMPACT-NOW update 6:new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading[J]. Brain Pathol, 2020, 30:844-856.
[14] Louis DN, Wesseling P, Paulus W, Giannini C, Batchelor TT, Cairncross JG, Capper D, Figarella-Branger D, Lopes MB, Wick W, van den Bent M. cIMPACT-NOW update 1:Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC)[J]. Acta Neuropathol, 2018, 135:481-484.
[15] Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, Kleinschmidt-DeMasters BK, Perry A, Reifenberger G, Stupp R, von Deimling A, Weller M. cIMPACT-NOW update 3:recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade Ⅳ"[J]. Acta Neuropathol, 2018, 136:805-810.
[16] Brat DJ, Aldape K, Colman H, Figrarella-Branger D, Fuller GN, Giannini C, Holland EC, Jenkins RB, Kleinschmidt-DeMasters B, Komori T, Kros JM, Louis DN, McLean C, Perry A, Reifenberger G, Sarkar C, Stupp R, van den Bent MJ, von Deimling A, Weller M. cIMPACT-NOW update 5:recommended grading criteria and terminologies for IDH-mutant astrocytomas[J]. Acta Neuropathol, 2020, 139:603-608.
[17] Louis DN, Giannini C, Capper D, Paulus W, Figarella-Branger D, Lopes MB, Batchelor TT, Cairncross JG, van den Bent M, Wick W, Wesseling P. cIMPACT-NOW update 2:diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant[J]. Acta Neuropathol, 2018, 135:639-642.
[18] Ellison DW, Hawkins C, Jones DTW, Onar-Thomas A, Pfister SM, Reifenberger G, Louis DN. cIMPACT-NOW update 4:diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF(V600E) mutation[J]. Acta Neuropathol, 2019, 137:683-687.
[19] Ellison DW, Aldape KD, Capper D, Fouladi M, Gilbert MR, Gilbertson RJ, Hawkins C, Merchant TE, Pajtler K, Venneti S, Louis DN. cIMPACT-NOW update 7:advancing the molecular classification of ependymal tumors[J]. Brain Pathol, 2020, 30:863-866.
[20] Rushing EJ. WHO classification of tumors of the nervous system:preview of the upcoming 5th edition[J]. Memo, 2021, 14:188-191.
[21] Wen PY, Packer RJ. The 2021 WHO Classification of Tumors of the Central Nervous System:clinical implications[J]. Neuro Oncol, 2021, 23:1215-1217.
[22] Yu SZ. Attention should be paid to understanding the clinical and pathological characteristics of rare subtypes of glioblastoma[J]. Zhonghua Bing Li Xue Za Zhi, 2015, 44:297-300.[于士柱. 应重视对胶质母细胞瘤少见亚型临床及病理学特征的认识[J]. 中华病理学杂志, 2015, 44:297-300.]
[23] Yang XJ, Jiang T. Clinical diagnosis and treatment of glioma[J]. Zhonghua Shen Jing Yi Xue Za Zhi, 2020, 19:1189-1193.[杨学军, 江涛. 脑胶质瘤的临床诊治撷要[J]. 中华神经医学杂志, 2020, 19:1189-1193.]
[24] Sun CR, Xu JH, Zhang BY, Xu SS, Dong F, Wei BX, Jiang B, Zhang JM. Interpretation on pediatric-type diffuse gliomas in the 2021 WHO Classification of Tumors of the Central Nervous System (fifth edition)[J]. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2021, 21:791-803. [孙崇然, 许晶虹, 张布衣, 许素素,董飞, 卫博星, 蒋飚, 张建民. 2021年世界卫生组织中枢神经系统肿瘤分类(第五版)儿童型弥漫性胶质瘤分类解读[J]. 中国现代神经疾病杂志, 2021, 21:791-803.]
[25] Li Z. Introduction of newly identified tumor types in the 2021 WHO Classification of Tumors of the Central Nervous System (fifth edition)[J]. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2021, 21:769-782. [李智. 2021年世界卫生组织中枢神经系统肿瘤分类(第五版)新增肿瘤介绍[J]. 中国现代神经疾病杂志, 2021, 21:769-782.]
[26] Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi ME, Horbinski C, Huang RY, Lassman AB, Le Rhun E, Lim M, Mehta MP, Mellinghoff IK, Minniti G, Nathanson D, Platten M, Preusser M, Roth P, Sanson M, Schiff D, Short SC, Taphoorn MJB, Tonn JC, Tsang J, Verhaak RGW, von Deimling A, Wick W, Zadeh G, Reardon DA, Aldape KD, van den Bent MJ. Glioblastoma in adults:a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions[J]. Neuro Oncol, 2020, 22:1073-1113.

选择文件类型/文献管理软件名称

选择包含的内容

2 世界卫生组织中枢神经系统肿瘤分类的演变：1979-2021年

The evolution of WHO Classification of Tumors of the Central Nervous System from 1979 to 2021

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	佟志勇. 颅内动脉瘤与脑血管重建术[J]. 中国现代神经疾病杂志, 2024, 24(8): 595-598.
[2]	佟志勇. 脑血管重建术历史沿革[J]. 中国现代神经疾病杂志, 2024, 24(8): 599-605.
[3]	金凌骥, 胡俊文, 李寅, 王林. 复杂颅内动脉瘤的颅内-颅内血管搭桥术[J]. 中国现代神经疾病杂志, 2024, 24(8): 606-612.
[4]	刘佩玺, 史源, 朱巍. 血流导向时代颅内全域脑血管搭桥术治疗颅内动脉瘤之应用方略[J]. 中国现代神经疾病杂志, 2024, 24(8): 613-618.
[5]	ApoE ε4与阿尔茨海默病专家共识编写组, 中国人体健康科技促进会神经变性病专业委员会, 国家神经系统疾病临床医学研究中心烟台区域分中心. ApoE ε4检测在阿尔茨海默病临床实践中的规范应用专家共识[J]. 中国现代神经疾病杂志, 2024, 24(8): 657-667.
[6]	张峰, 孟凡刚. 帕金森病自主神经功能障碍丘脑底核脑深部电刺激术治疗进展[J]. 中国现代神经疾病杂志, 2024, 24(7): 510-515.
[7]	吴桂智, 田宏. Meige综合征脑深部电刺激术治疗进展[J]. 中国现代神经疾病杂志, 2024, 24(7): 516-521.
[8]	孟凡刚, 张建国. 耳后磨骨槽技术在脑深部电刺激术中的应用[J]. 中国现代神经疾病杂志, 2024, 24(7): 522-524.
[9]	陈琳, 潘华. 功能性震颤的电生理诊断[J]. 中国现代神经疾病杂志, 2024, 24(7): 573-578.
[10]	魏俊吉, 常健博. 深入基层医院普及神经外科重症管理理念[J]. 中国现代神经疾病杂志, 2024, 24(6): 403-406.
[11]	中华医学会神经外科学分会, 中国神经外科重症管理协作组. 舒巴坦治疗神经外科重症患者鲍曼不动杆菌感染中国专家共识[J]. 中国现代神经疾病杂志, 2024, 24(6): 407-424.
[12]	史若琳, 高秀洁, 崔家宁, 邵妍, 谢璐霜, 刘毅. 5-羟色胺与帕金森病非运动症状研究进展[J]. 中国现代神经疾病杂志, 2024, 24(6): 497-501.
[13]	李海峰. 在进入靶向治疗的时代激素仍然是重症肌无力治疗的基础[J]. 中国现代神经疾病杂志, 2024, 24(5): 295-307.
[14]	许鸿嘉, 舒崖清, 王蘋, 李蕃, 许顺良, 邱伟, 马晓宇. 抗水通道蛋白4抗体阳性视神经脊髓炎谱系疾病诊断与治疗进展[J]. 中国现代神经疾病杂志, 2024, 24(5): 308-314.
[15]	黄瑀, 廖金池, 舒崖清. 抗N-甲基-D-天冬氨酸受体脑炎睡眠障碍研究进展[J]. 中国现代神经疾病杂志, 2024, 24(5): 315-319.

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

2 世界卫生组织中枢神经系统肿瘤分类的演变：1979-2021年

The evolution of WHO Classification of Tumors of the Central Nervous System from 1979 to 2021

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价